Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.

Breast Cancer Res · 2012 · PMC3446332 · PMID 22551440

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Predictive value of p53 status In keeping with efficacy results in the entire BIG 02-98 population, this substudy population showed a favorable trend but not a significant benefit in DFS from the addition of docetaxel (HR = 0.77, 95% CI: 0.56 to 1.06).

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.